NCT06399354Completed
The Effect of Medium-chain Fatty Acids on Cardiac Function
Source: ClinicalTrials.gov · Last updated 6 Apr 2025
Brief summary (registry, in English)
The effect of an acute intake of medium-chain fatty acids on heart function measured by cardiac magnetic resonance imaging (CMR) will be measured in individuals with heart failure with reduced ejection fraction (HFrEF) and in matched healthy controls with normal heart function. This aim will be investigated in a cross-over study including two visits: acute intake of medium-chain fatty acid or long-chain fatty acid as control. In addition, the effect of acute medium-chain fatty acid compared with long-chain fatty acid intake on whole-body lipid and glucose metabolism will be investigated.. The hypothesis is that acute consumption of medium-chain fatty acid will improve cardiac function in patients with heart failure.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 20 Aug 2024
- Primary completion date
- 1 Apr 2025
- Lead sponsor
- University of Copenhagen
- Diseases
- Heart failure
- NCT number
- NCT06399354
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 20 Aug 2024 to the primary completion date, 1 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Blood donation during and \< 3 month prior to study
Other illness
- Diabetes, kidney or liver disease.
- Contraindications to CMR, e.g., abdominal height exceed limitations of the MR- scanner, pacemaker, stent, neurostimulator, or other electronic device implanted, implanted metal devices, severe claustrophobia, or physiological diseases
Lab values
- To ensure safety, no gadobutrol contrast can be administrered to participants with severe reduced kidney function, indicated by glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2, accessed from the obtained screening blood sample or from the Patient Record. In such cases, potential participants will be excluded from the study.
Other
- Pregnant, lactating or planning to become pregnant within the study period
- Simultaneous participation in other clinical trials
- Inability, physically or mentally, to comply with the procedure required by the study protocol ad evaluated by the primary investigator, study manager or clinical responsible
Who the study is looking for
- Heart failure with reduced ejection fraction; I. Left ventricular ejection fraction ≤45% and optimal, stable HFrEF treatment according to guidelines II. Functional classification New York Heart Association class II-III.
- No uncorrected cardiac valvular disease
- No signs or symptoms of myocardial infarction within the previous 3 months
- No permanent of persistent arterial fibrillation.
- For controls:
- No use of medications with influence on heart function
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Copenhagen Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.